MRSA | German Center for Infection Research

Short description

MRSA are Staphylococcus-aureus strains that are resistant against all available beta-lactam antibiotics.

Synonyms

Methicillin-resistant Staphylococcus aureus

Detailed description

MRSA usually cause wound infections and inflammations of the airways. Initially, they were mainly observed in hospitals. Today, they are also found outside of hospitals, in food, livestock and the environment. Beta-lactam antibiotics such as penicillin are not effective against them anymore. Usually, these strains are multidrug-resistant and thus not sensitive to other antibiotic classes. A small proportion of the population is colonized with MRSA, without having fallen ill yet.

Tanja Schneider presenting the PHOENIX award

Prof. Tanja Schneider receives PHOENIX Pharmacy Science Award

Prof. Tanja Schneider, Head of the Institute of Pharmaceutical Microbiology at the University Hospital Bonn (UKB) and Deputy Coordinator of the “New Antibiotics” research area at the German Center for

Banner der WHO zur World AMR Awareness Week 2024

World AMR Awareness Week 2024, 18-24 November – Educate. Advocate. Act now.

Antimicrobial resistance (AMR) is one of the most urgent challenges facing global health and development. Described as a “creeping pandemic” by the G7 forum of leading economic nations, AMR occurs

Several mustard-coloured, spherical bacteria in the middle of much smaller blue-coloured blood cells.

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus in the nasal microbiome

The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen

Apr 2024

JAC Antimicrob Resist

Individual and institutional predisposing factors of MRSA surgical site infection and outcomes-a retrospective case-control-study in 14 European high-volume surgical centres

Autoren

Rutz J et al.

Innovative Phage Lysin HY-133 enters phase I clinical study

HYpharm's innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against the bacterial pathogen Staphylococcus aureus including multi-resistant

Sep 2023

Int J Antimicrob Agents

Detection and evaluation of the antimicrobial activity of Micrococcin P1 isolated from commensal and environmental staphylococcal isolates against MRSA

Autoren

Fernández-Fernández R et al.

The photo shows a group of four researchers (three women and one man) in white lab coats in a laboratory.

Researchers decode new antibiotic agent

More and more bacterial pathogens are developing resistance. There is an increasing risk that current drugs will no longer be effective against infectious diseases. Scientists around the world are

Apr 2023

Infection

Decrease in vancomycin MICs and prevalence of hGISA in MRSA and MSSA isolates from a German pediatric tertiary care center

Autoren

Haas K et al.

Several silver-coloured bioreactors with many connecting tubes and control screens used for fermentation and production of active agents.

Clinical development of two antimicrobial agents funded by Else Kröner-Fresenius Foundation

The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct

Dec 2022

Pharmaceutics

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

Autoren

Rox K et al.